T cell exhaustion is a common feature of chronic infections and cancer that limits viral or tumor control. A major breakthrough was the demonstration that T cell exhaustion could be reversed by targeting inhibitory receptors such as PD1 and LAG3 and that synergy exists between these receptors. Recent cancer clinical trials demonstrated robust responses following targeted blockade of PD1 with additional trials underway for LAG3. Despite the clinical promise, these inhibitory receptors also control tolerance and autoimmunity and combined genetic deficiency in PD1 and LAG3 in mice results in severe multiorgan autoimmunity. Little is known about the cellular and molecular mechanism by which PD1 and LAG3, and the synergy between them, regulates T cell exhaustion versus autoimmunity. Moreover, it is unclear whether blockade in vivo has similar effects on CD8+ T cells and CD4+ T cells or whether different aspects of exhaustion are regulated by these receptors in each lineage. However, defining the cellular and molecular mechanisms of by which these receptors operate independently and synergistically is critical to understanding the balance between effective immunity to chronic infections and tumors and self-tolerance. Thus, our hypothesis is that the synergy between the PD1 and LAG3 pathways operates via a combination of cellular and molecular mechanisms that differ between CD8+ and CD4+ T cells during chronic viral infection. We will test this hypothesis in the following Aims:
AIM 1 : Does disruption of PD1 and LAG3 signals cooperate for molecular as well as cellular synergy in the reversal of CD8+ T cell exhaustion during chronic viral infection? Thus, we will use novel genetic strategies combined with blockade in vivo during chronic viral infection to test: (1) whether individual or combined signals from these pathways regulate the induction of CD8+ T cell exhaustion; (2) whether PD1 and/or LAG3 have extrinsic as well as intrinsic roles in regulating established CD8+ T cell exhaustion and define whether cell intrinsic synergy exist for these inhibitory receptors; (3) if synergy is due to preferential reinvigoration of distinct subsets of exhausted CD8+ T cells; and (4) whether key transcriptional changes defining the combinatorial signals from PD1 and LAG3 can define molecular mechanisms of synergy.
AIM 2 : Do PD1 and LAG3 signals control the development and reversibility of CD4+ T cell exhaustion during chronic viral infection through molecular and/or cellular pathways? Specifically, we will test: (1) whether these pathways are required for the development of CD4+ T cell exhaustion; (2) whether they control established CD4+ T cell exhaustion and define whether PD1 and LAG3 synergize to control CD4+ T cell exhaustion; (3) if subpopulations of exhasuted CD4+ T cells have different depenency on PD1 and LAG3; and (4) whether specific molecular pathways downstreatm of PD1 and/or LAG3 control CD4+ T cell exhaustion.

Public Health Relevance

Chronic infections with viruses such as HIV, HCV and HBV affect half a billion people and are significant causes of morbidity and mortality. T cell dysfunction or ?exhaustion? is a major immunological defect during these infections and can be modeled with LCMV infection in mice. The studies proposed will define the role of the inhibitory receptors PD-1 and LAG-3 in CD8+ and CD4+ T cell exhaustion and provide new insights into how to reverse and avoid T cell exhaustion and improve immunity during these and other chronic infections.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI108545-03
Application #
9258392
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Overacre-Delgoffe, Abigail E; Vignali, Dario A A (2018) Treg Fragility: A Prerequisite for Effective Antitumor Immunity? Cancer Immunol Res 6:882-887
Stelekati, Erietta; Chen, Zeyu; Manne, Sasikanth et al. (2018) Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155. Cell Rep 23:2142-2156
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Ratay, Michelle L; Glowacki, Andrew J; Balmert, Stephen C et al. (2017) Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease. J Control Release 258:208-217
Huang, Alexander C; Postow, Michael A; Orlowski, Robert J et al. (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60-65
Hope, Jennifer L; Stairiker, Christopher J; Spantidea, Panagiota I et al. (2017) The Transcription Factor T-Bet Is Regulated by MicroRNA-155 in Murine Anti-Viral CD8+ T Cells via SHIP-1. Front Immunol 8:1696
Andrews, Lawrence P; Marciscano, Ariel E; Drake, Charles G et al. (2017) LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276:80-96
Chen, Zeyu; Stelekati, Erietta; Kurachi, Makoto et al. (2017) miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb. Cell Rep 20:2584-2597
Zhang, Qianxia; Chikina, Maria; Szymczak-Workman, Andrea L et al. (2017) LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci Immunol 2:
Kurachi, Makoto; Kurachi, Junko; Chen, Zeyu et al. (2017) Optimized retroviral transduction of mouse T cells for in vivo assessment of gene function. Nat Protoc 12:1980-1998

Showing the most recent 10 out of 21 publications